The dose-findings studies reported here not only documented the superior efficacy of GLP1/E in the management of metabolic alterations in our obese PCOS model, including lowering body weight and adiposity, as well as improvement of glucose handling and insulin resistance, but also highlighted a non-monotonic effect of this dual agonist in PNA mice, with optimal effects being achieved with submaximal doses
Angarita, G
Based on Phase 2 trial data, noticeable weight loss typically becomes apparent between months 3 and 6, with results continuing to accumulate through 48 weeks at higher doses
Average weight loss was under 4% for those who stopped treatment early, versus nearly 7% or those who stopped later on, the study says
Individual response magnitude varies widely based on genetic, metabolic, and lifestyle factors
Semaglutide Unlike retatrutide, semaglutide is a single hormone receptor agonist